Quantum Cyber N.V. (QUCY) SEC filings document a Nasdaq-listed issuer whose public record includes both its former Mainz Biomed N.V. identity and its newer autonomous defense technology focus. The company’s quarterly reports and 8-K filings are important because they describe material agreements, license arrangements, property acquisition activity, capital structure matters, governance items, and operating and financial results.
For QUCY, quarterly reports can show how the company reports expenses, liabilities, share issuance, and historical operating results. Recent quarterly disclosure describes the exclusive LightShift license for quantum photonic array technology, the related accounting treatment, and the company’s issued ordinary shares. Earlier quarterly disclosure also discusses ColoAlert sales and the wind down of the prior colorectal cancer screening sales and marketing team.
Material 8-K filings are especially relevant for Quantum Cyber because they have covered the Project LightShift intellectual property license, an amendment involving BP United manufacturing and consulting services, termination of an at-the-market issuance sales agreement, a change in independent registered public accounting firm, investor presentation materials, and the Bridgeport property acquisition involving Quantum Drones Corporation and Arcade Realty LLC.
Annual reports, proxy statements, and Form 4 insider transaction reports, when available, add context on risk factors, governance, executive compensation, ownership changes, and insider trading activity. Plain-language filing summaries can help readers separate core disclosures from legal formatting, with particular attention to 10-Q reports, 10-K annual reports, Form 4 transactions, and 8-K material event filings tied to QUCY’s defense technology and manufacturing strategy.
Mainz Biomed N.V. entered into an asset purchase agreement on April 9, 2026 to sell the intellectual property for its next generation colorectal cancer screening product candidates to an Italian buyer for $1.25 million. Closing is expected by April 23, 2026, subject to standard conditions and certain third-party consents, shipments and patent-related deadlines.
The company plans to use net proceeds to settle outstanding liabilities and for general corporate purposes. Management reiterates that winding down ColoAlert and next generation colorectal programs allows focus on a pancreatic cancer detection candidate and exploration of post-quantum cybersecurity opportunities.
Mainz Biomed previously reported stockholders’ equity of $641,600, below the $2.5 million minimum in Nasdaq Listing Rule 5550(b)(1). After receiving a total equity investment of $6 million in preferred shares in February and March 2026 and reducing monthly expenditures, the company believes its stockholders’ equity now exceeds $2.5 million and that it is currently in compliance with the Nasdaq listing requirement.
Mainz Biomed N.V. reported a net loss of $16.2 million for 2025 and disclosed substantial doubt about its ability to continue as a going concern. Revenue fell to $0.5 million, mainly from ColoAlert sales in Europe, while operating losses were driven by R&D, SG&A, and a $2.64 million impairment on colorectal cancer IP.
The company is exiting its colorectal cancer business, selling ColoAlert IP and focusing on a lower-cost pancreatic cancer screening program. It ended 2025 with $0.9 million in cash and a working capital deficit of about $1.9 million, and it later raised $6 million via preferred stock and a strategic investment from David Lazar that could control over 90% of fully diluted shares after shareholder approval.
Mainz also plans a strategic expansion into post-quantum cybersecurity under the Quantum Cyber brand and faces Nasdaq minimum bid price deficiency, with until September 16, 2026 to regain compliance. The audit opinion highlights going-concern risk, and the company expects to rely on additional equity and debt financing to fund operations.
Mainz Biomed N.V. has called an extraordinary shareholders’ meeting on April 22, 2026 to vote on a transformative financing and capital structure package, board changes and governance items. Shareholders are being asked to ratify Reliant CPA as auditor and approve issuances of ordinary shares underlying five series of preferred shares issued or to be issued to investor David E. Lazar to comply with Nasdaq Listing Rules 5635(b) and 5635(d). The preferred shares, once fully convertible, would represent in excess of 95% of issued and outstanding ordinary shares on a fully diluted basis after a planned second $3 million closing.
Further proposals would authorize specific conversion ratios for all five preferred series, increase authorized capital to up to 900,000,000 ordinary shares and 100,000,000 preferred shares on a post–reverse split basis, change the company’s name to Quantum Cyber N.V., and approve a reverse share split in a range of 1‑for‑2 to 1‑for‑100 to help regain Nasdaq’s $1.00 minimum bid price after a deficiency notice. Shareholders will also vote on appointing four directors (including Lazar as CEO), expanding the 2025 Omnibus Incentive Plan to 10,000,000 ordinary shares, updating the remuneration policy and formally approving board resolutions related to the Lazar purchase agreement. The company warns that failure to obtain approvals could block the final closing, leave restrictive covenants in place, constrain new financing and potentially force a sale of assets or receivership.
Mainz Biomed N.V. reported that Nasdaq has notified the company its ordinary shares no longer meet the minimum $1.00 bid price requirement, after trading below that level for 30 consecutive business days from February 5 to March 19, 2026. The company has 180 calendar days, until September 16, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for ten consecutive business days. If it does not regain compliance by then, it may qualify for an additional 180‑day period if it meets other initial listing standards and formally indicates an intention to cure, potentially via a reverse stock split. The notice has no immediate effect on the current Nasdaq listing, but failure to cure the deficiency could ultimately lead to delisting, which the company would have the right to appeal.